Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review

Pisanu, Claudia; Severino, Giovanni; Toma, Ilario De; Dierssen, Mara; Fusar‐Poli, Paolo; Gennarelli, Massimo; Lio, Pietro; Maffioletti, Elisabetta; Maron, Eduard; Minelli, Alessandra; Potier, Marie‐Claude; Serretti, Alessandro; Stacey, David; Westrhenen, Roos van; Xicota, Laura; Baune, Bernhard T.; Squassina, Alessio

doi:10.1016/j.euroneuro.2021.12.005

Cited by 8 publications

(12 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past few years, a considerable amount of research has been conducted to examine the role of miRNAs in neuropsychiatric disease [147][148][149][150][151][152][153][154][155][156]. We and other investigators have examined the expression of miRNAs in human postmortem brains of depressed subjects, in the brain of animals showing depression-like behavior, and in peripheral tissues such as blood, urine, and saliva [6,96,144,150,[157][158][159][160][161][162][163][164][165][166][167]. We have demonstrated that miRNAs form highly correlated networks in the brains of MDD subjects that differ from healthy controls, suggesting that miRNA networks can give rise to specific behavioral phenotypes [96,168,169].…”

Section: Studies Of Dna Methylation In Adolescents With Elsmentioning

confidence: 99%

Dissecting early life stress-induced adolescent depression through epigenomic approach

Ochi

Dwivedi

2022

Mol Psychiatry

View full text Add to dashboard Cite

Early life stress (ELS), such as abuse and neglect during childhood, can lead to psychiatric disorders in later life. Previous studies have suggested that ELS can cause profound changes in gene expression through epigenetic mechanisms, which can lead to psychiatric disorders in adulthood; however, studies on epigenetic modifications associated with ELS and psychiatric disorders in adolescents are limited. Moreover, how these epigenetic modifications can lead to psychiatric disorders in adolescents is not fully understood. Commonly, DNA methylation, histone modification, and the regulation of noncoding RNAs have been attributed to the reprogramming of epigenetic profiling associated with ELS. Although only a few studies have attempted to examine epigenetic modifications in adolescents with ELS, existing evidence suggests that there are commonalities and differences in epigenetic profiling between adolescents and adults. In addition, epigenetic modifications are sex-dependent and are influenced by the type of ELS. In this review, we have critically evaluated the current evidence on epigenetic modifications in adolescents with ELS, particularly DNA methylation and the expression of microRNAs in both preclinical models and humans. We have also clarified the impact of ELS on psychiatric disorders in adolescents to predict the development of neuropsychiatric disorders and to prevent and recover these disorders through personalized medicine.

show abstract

Section: Studies Of Dna Methylation In Adolescents With Elsmentioning

confidence: 99%

Dissecting early life stress-induced adolescent depression through epigenomic approach

Ochi

Dwivedi

2022

Mol Psychiatry

View full text Add to dashboard Cite

show abstract

“…Similarly, transcriptional biomarkers of response to pharmacological treatments have also been investigated, still with not unequivocal results yet. A recent review covers this issue [ 35 ].…”

Section: Biomarkers In Major Depressive Disordersmentioning

confidence: 99%

Clinical Utility of Fluid Biomarker in Depressive Disorder

Serretti

2022

Clin Psychopharmacol Neurosci

Self Cite

View full text Add to dashboard Cite

Major depressive disorders are ranked as the single largest contributor to non-fatal health loss and biomarkers could largely improve our routine clinical activity by predicting disease course and guiding treatment. However there is still a dearth of valid biomarkers in the field of psychiatry. The initial assumption that a single biomarker can capture the myriad of complex processes proved to be naive. The purpose of this paper is to critically review the field and to illustrate the possible practical application for routine clinical care. Biomarkers derived from DNA analysis are the ones that have received the most attention. Other potential candidates include circulating transcription products, proteins, and inflammatory markers. DNA polygenic risk scores proved to be useful in other fields of medicine and preliminary results suggest that they could be useful both as risk and diagnostic biomarkers also in depression and for the choice of treatment. A number of other possible fluid biomarkers are currently under investigation for diagnosis, outcome prediction, staging, and stratification of interventions, however research is still needed before they can be used for routine clinical care. When available, clinicians may be able to receive a lab report with detailed information about disease risk, outcome prediction, and specific indications about preferred treatments.

show abstract

“…Kontou et al identified and meta-analyzed four studies containing gene expression data in patients with myocardial infarction and healthy controls (17). Pisanu et al conducted a systematic review with qualitative synthesis of 123 gene expression studies in patients with psychiatric disorders characterized for response (18). Recently, Ibrahim et al conducted a non-PRISMA systematic review and meta-analysis of gene expression signatures corresponding to fluoxetine treatment in rodents (19).…”

Section: Introductionmentioning

confidence: 99%

Gene expression signatures of response to fluoxetine treatment: systematic review and meta-analyses

Cooper,

Cowden,

Stanley

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundSelecting the best antidepressant for a patient with major depressive disorder (MDD) remains a challenge, and some have turned to genomic (and other ‘omic) data to identify an optimal therapy. In this work, we synthesized gene expression data for fluoxetine treatment in both human patients and rodent models, to better understand biological pathways affected by treatment, as well as those that may distinguish clinical or behavioral response.MethodsFollowing the PRISMA guidelines, we searched the Gene Expression Omnibus (GEO) for studies profiling humans or rodent models with treatment of the antidepressant fluoxetine, excluding those not done in the context of depression or anxiety, in an irrelevant tissue type, or with fewer than three samples per group. Included studies were systematically reanalyzed by differential expression analysis and Gene Set Enrichment Analysis (GSEA). Individual pathway and gene statistics were synthesized across studies by three p-value combination methods, and then corrected for multiple testing.ResultsOf the 74 data series that were screened, 20 were included: 18 in rodents, and two in tissue from human patients. Studies were highly heterogeneous in the comparisons of both treated vs. control samples and responders vs. non-responders, with 737 and 356 pathways, respectively, identified as significantly different between groups in at least one study. 19 pathways were identified as consistently different in responders vs. non-responders, including Toll Like Receptor (TLR) and other immune pathways. Signal transduction pathways were identified as consistently affected by fluoxetine treatment in depressed patients and rodent models.DiscussionThese meta-analyses confirm known pathways and provide new hints toward antidepressant resistance, but more work is needed. Most included studies involved rodent models, and both patient studies had small cohorts. Additional large-cohort studies applying additional ‘omics technologies are necessary to understand the intricacies and heterogeneity of antidepressant response.

show abstract

Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review

Cited by 8 publications

References 152 publications

Dissecting early life stress-induced adolescent depression through epigenomic approach

Dissecting early life stress-induced adolescent depression through epigenomic approach

Clinical Utility of Fluid Biomarker in Depressive Disorder

Gene expression signatures of response to fluoxetine treatment: systematic review and meta-analyses

Contact Info

Product

Resources

About